Expression of membrane/soluble MHC class I chain-related molecule A and NKG2D receptor in osteosarcoma and its clinical significance.
- Author:
Ping XIAO
1
;
Ling XUE
;
Li-hong CHE
;
Hui-xi WU
;
Hui QIAO
Author Information
- Publication Type:Journal Article
- MeSH: Bone Neoplasms; blood; metabolism; pathology; Cell Differentiation; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Histocompatibility Antigens Class I; blood; metabolism; Humans; Immunohistochemistry; Lymphocytes; immunology; NK Cell Lectin-Like Receptor Subfamily K; metabolism; Neoplasm Staging; Osteosarcoma; blood; metabolism; pathology
- From: Chinese Journal of Pathology 2007;36(9):596-599
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the expression of membrane MICA (mMICA), soluble MICA (sMICA) and NKG2D receptor in cases of osteosarcoma and to analyze its clinical significance.
METHODSExpression of mMICA in osteosarcoma tissue of 43 cases was detected with immunohistochemistry. Expression of NKG2D in peripheral blood lymphocytes of 16 cases was analyzed by flow cytometry. Serum level of soluble MICA (sMICA) was measured by ELISA.
RESULTSmMICA was widely expressed in osteosarcoma tissue (37/43). Expression of NKG2D in peripheral blood lymphocytes was significantly decreased. High levels of mMICA and NKG2D expression were associated with better differentiation and earlier tumor stage of osteosarcoma (P < 0.05). A significant increase in serum level of sMICA was demonstrated in patients with metastasis and advanced tumor.
CONCLUSIONSThe mMICA expression in tumor tissue, NKG2D expression in peripheral lymphocytes and serum sMICA level correlate with the differentiation and stage of osteosarcoma. These parameters may thus represent potential diagnostic and prognostic markers in patients with osteosarcoma. Manipulation of the MICA-NKG2D pathway may become a target of immunotherapy for osteosarcoma.
